Cancer Teon Therapeutics patents new heterocyclic CD73 inhibitors April 29, 2024 Teon Therapeutics Inc. has identified new heterocyclic 5’-nucleotidase (CD73) inhibitors reported to be useful for the treatment of cancer.Read More
Cancer Teon Therapeutics presents new CD73 inhibitors April 19, 2024 Teon Therapeutics Inc. has divulged 5’-nucleotidase (CD73) inhibitors reported to be useful for the treatment of cancer.Read More
Endocrine/Metabolic Teon Therapeutics describes new adenosine A2B receptor antagonists Feb. 12, 2024 Teon Therapeutics Inc. has identified prodrugs of adenosine A2B receptor (ADORA2B) antagonists.Read More
Cancer Teon Therapeutics identifies new cannabinoid CB2 receptor modulators for cancer May 26, 2023 Teon Therapeutics Inc. has reported 4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide...Read More
